- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00535522
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Greenbaum Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- The subject has a histologically confirmed advanced non-hematologic malignancy.
- The subject has a chemotherapy-free interval of at least 4 weeks prior to first dose of study drug.
- The subject is intolerant of, is not a candidate for, or the subject's disease is refractory to established therapy known to provide clinical benefit for their disease.
- A female subject of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study, and for 30 days after the last dose of study drug. Male subjects should agree to use contraception for the duration of the study, and for 30 days after the last dose of study drug.
- The subject has a life expectancy of greater than 12 weeks.
- The subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
- The subject has the ability to swallow and retain oral medication
The subject's most recent test values within 2 weeks before the date of entry meet the following standards:
Bone marrow function:
- Absolute neutrophil count ≥1500/mm3
- Hemoglobin ≥9.0g/dL, platelet count ≥100,000/mm3.
Liver function:
- Total bilirubin ≤1.5 times the upper limit of the standard value of each institution
- Aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper limit of the standard value of each institution.
Renal function:
- Serum creatinine ≤1.5 times the upper limit of the standard value of each institution.
- In the recommended phase 2 dose Cohort, the subject has an accessible tumor for biopsy and is willing to undergo 2 tumor biopsies.
- In the recommended phase 2 dose Cohort, the subject has at least 1 measurable lesion based on the treatment assessment standards for solid tumors.
- In the recommended phase 2 dose Cohort, the subject has a tumor that expresses EGFR and/or overexpresses erbB2.
Exclusion Criteria
- The subject has a symptomatic brain metastasis.
- The subject has an uncontrollable pleural effusion, ascitic fluid, or pericardial effusion.
- The subject has active gastrointestinal bleeding as evidenced by either hematemesis or melena.
- The subject has acute gastrointestinal ulcers.
- The subject has been treated with a small molecule inhibitor of EGFR or HER2 (except for lapatinib).
- The subject has a history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
- The subject has significant cardiovascular impairment (history of New York Heart Association class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to study drug treatment.
- The subject has a severe disease (other than cancer) that will likely affect the prospects of survival or a history that will make it difficult to appropriately manage and follow his or her progress in accordance with the protocol (serious organ disorder, mental illness, drug abuse, alcohol dependency, etc.).
- The subject requires prohibited treatment (drug, surgery or radiotherapy for treatment of malignant tumor, drugs that could interact with TAK-285) except for radiotherapy of limited area (<20% of total bone marrow) in order to relieve the symptoms from symptomatic bone metastasis.
- The subject who has been treated with a drug, which inhibits or induces Cytochrome P450 3A4 within 1 week prior to the start of treatment with the investigational drug.
- The subject is pregnant or breast feeding.
- The subject has participated in another clinical study/postmarketing clinical study within 4 weeks prior to the start of treatment with TAK-285.
The subject is currently taking excluded medications, including:
- Concurrent anticancer therapy with agents other than TAK-285.
The following prohibited medications and substances should not be used for at least 7 days prior to the start of the study and throughout completion:
Strong CYP3A4 inhibitors
- Amiodarone
- Diltiazem
- Verapamil
- Human immunodeficiency virus protease inhibitors
- itraconazole
- ketoconazole
- macrolide antibiotics (excluding azithromycin)
Strong CYP3A4 inducers
- Carbamazepine
- Efavirenz
- Nevirapine
- Phenytoin
- Rifabutin
- Rifampin.
- St. John's wort
- Medications and devices containing hormones such as oral contraceptives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAK-285
|
TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off.
Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety profile, including dose-limiting toxicities, maximum tolerated dose, recommended Phase II dose; and the pharmacokinetic profile.
Time Frame: Duration of study
|
Duration of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective disease response by modified Response Evaluation Criteria in Solid Tumors.
Time Frame: Duration of study
|
Duration of study
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TAK-285_101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of Colorado, DenverRecruitingCancer | Childhood CancerUnited States
-
New Mexico Cancer Care AllianceOhio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center...RecruitingCancer | Cancer RiskUnited States
Clinical Trials on TAK-285 Dose Escalation Cohorts
-
Qualigen Theraputics, Inc.Translational Drug DevelopmentRecruiting
-
Gilead SciencesCompletedHepatitis B | HBVKorea, Republic of, United States, Canada, Australia, New Zealand
-
Gilead SciencesCompletedHepatitis CUnited States, Puerto Rico
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina